Cohorts A2 (single agent high dose in adjuvant setting) and B1 (low dose added to anti-PD-1) have been opened and first patient of cohort A2 has been dosed
Liège, Belgium and Grenoble, France...
PDC*line Pharma strengthens its board of directors with an
industry leader in the field of immuno-oncology
Liège, Belgium and Grenoble, France, June 25, 2020 – PDC*line Pharma, a clinical stage...
We are very pleased to announce the publication in OncoImmunology of the results of the first in-human trial with our innovative plasmacytoid dendritic cell line based cancer vaccine in melanoma...
Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today...
Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces...
Liège, Belgium, and Grenoble, France, September 9, 2019 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces...
Liège, Belgium, and Grenoble, France, May 7, 2019 - PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today...
- PDC*line Pharma grants exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer...
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer...
Eric Halioua, CEO of PDC*line Pharma will be speaker at an official satellite workshop at BIO US (San Diego, CA – US) to present the company strategy for new immunotherapies. The workshop entitled “Wi...
